- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05854706
The Effect of Theta-burst Stimulation on Serum BDNF
Antidepressant Effect of Prolonged Intermittent Theta-burst Stimulation on Serum Brain-derived Neurotrophic Factor Levels of Patients With Depression: A Randomized, Double-Blind, Sham-Controlled Study
The goal of this clinical trial is to investigate the effect of theta burst stimulation for depression and serum brain-derived neurotrophic factor (BDNF) in individuals with major depression. The main question it aims to answer is whether 10 sessions of theta burst stimulation can influence the serum level of BDNF.
Participants will be randomized into active group and sham group. Researchers will compare the level of BDNF in these groups.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is an increasing evidence that the BDNF could be involved in the mode of action of antidepressants and, perhaps, of brain stimulation. Brain stimulation methods, such as electroconvulsive therapy (ECT) has been used to treat patients with severe depression and is reported to increase BDNF levels in blood. Numerous studies has demonstrated that repetitive transcranial magnetic stimulation (rTMS) as an alternative to ECT, produced the most robust antidepressant effects, and is the most widely applied treatment protocol for major depressive disorder (MDD). Theta-burst stimulation (TBS) is a novel form of rTMS, and has recently emerged as a method with the potential to produce similar anti-depressant effects much more rapidly than traditional repetitive TMS protocols. It is presumed that BDNF mediates the therapeutic benefits of brain rTMS, but previous results are contradictory.
Specific Aims:
The study is a four-week randomized, double-blind, sham-controlled study comparing pre- and post-treatment serum BDNF levels of patients with MDD, who receive active or sham of prolonged intermittent TBS (piTBS) treatment.
Method:
During the four-week double-blind phase of active or sham piTBS treatment, piTBS sessions are scheduled daily in a 5-day sequence for 10 sessions over two weeks. Symptomatic ratings and serum BDNF measurement are administered at baseline (W0, before brain stimulation), at the end of Week 2 brain stimulation treatments, and at the two-week follow-up after the treatment (Week 4). Otherwise, the symptomatic changes are also evaluated at the end of Week 1 brain stimulation. The study include sixty patients with major depression and all participants are randomly allocated (1:1) to groups receiving either active or sham piTBS group. The aim of the present study is to explore the effect of piTBS therapy on serum BDNF levels and change of depression symptom rating scale, as well as their associations in patients with MDD.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hu-Ming Chang
- Phone Number: 0978052951
- Email: DAU66@tpech.gov.tw
Study Locations
-
-
Taipei CITY
-
Taipei, Taipei CITY, Taiwan, 105
- Recruiting
- Taipei City Hospital
-
Contact:
- Hu-Ming Chang
- Phone Number: 0978052951
- Email: DAU66@tpech.gov.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age between 20 and 65 years;
- fulfilling the Diagnostic and Statistical Manual version 5 (DSM-5) criteria of Major depressive disorder assessed by the Structured Clinical Interview
Exclusion Criteria:
- Inability to provide informed consent or comprehend the study procedure;
- A major psychiatric illness including schizophrenia spectrum disorder, bipolar spectrum disorder, and major depressive disorder with psychotic features.
- A current DSM-5 diagnosis of substance use disorder except nicotine use disorder or the use of one to two low-potency benzodiazepine tablets for sleep impairment;
- Have known preexisting noise-induced hearing loss, concurrent treatment with ototoxic medications, or with cochlear implants.
- Unstable medical illness, including malignancy, uncontrolled diabetes mellitus, unstable cardiac disease or recent myocardial infarction, or cerebrovascular or cardiovascular risk factors that require intensive medical management
- On medications known to lower seizure threshold (e.g., TCA, bupropion, clozapine)
- Implants controlled by physiological signals, including pacemaker, implantable cardioverter defibrillator, cochlear implant.
- Metallic objects in the head, including stenting, suture.
- Elevated risk of seizure due to traumatic brain history, seizure history, and head trauma, intracranial lesion, and alcohol or benzodiazepines withdrawal syndrome, stimulant intoxication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active arm
Prolonged iTBS sessions are scheduled daily in a 5-day sequence for 10 sessions over two weeks
|
Theta Burst Stimulation
|
Sham Comparator: Sham arm
Sham stimulation sessions are scheduled daily in a 5-day sequence for 10 sessions over two weeks
|
Theta Burst Stimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in depression severity
Time Frame: Before intervention (week 0) and after intervention (week 2)
|
Measured by Montgomery-Asberg Depression Rating Scale (MADRS)
|
Before intervention (week 0) and after intervention (week 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in brain-derived neurotrophic factor (BDNF)
Time Frame: Before intervention (week 0) and after intervention (week 2)
|
Serum level of BDNF
|
Before intervention (week 0) and after intervention (week 2)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCHIRB-11003020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gambling Disorder
-
Université Catholique de LouvainCentre Hospitalier Universitaire Vaudois; Cliniques universitaires Saint-Luc-... and other collaboratorsUnknownCraving | Gambling | Gambling Disorder | Gambling, Pathological | Gambling ProblemSwitzerland
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingAccelerated rTMS in Gambling Disorder: a Multicentric, Randomized, Sham-controlled Trial (arTMSinGD)Gambling | Gambling Disorder | Gambling, Pathological | Gambling Problem
-
Region SkaneLund UniversityRecruitingGambling Disorder | Problem GamblingSweden
-
Universitat Jaume INot yet recruitingGambling Disorder | Problem GamblingSpain
-
University of ChicagoCompleted
-
Karolinska InstitutetCompleted
-
Finnish Institute for Health and WelfareUnknownNaloxone | Gambling Disorder | Opioid Antagonist | Pathological GamblingFinland
-
Region SkaneRecruitingGambling Disorder | Gaming DisorderSweden
-
Indonesia UniversityRadboud University Medical CenterNot yet recruiting
-
Karolinska InstitutetDeakin UniversityRecruiting
Clinical Trials on Theta Burst Stimulation
-
Erika ForbesNational Institute of Mental Health (NIMH)Completed
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
Nicholas Balderston, PhDRecruiting
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingCognitive Dysfunction | Memory Disorders in Old AgeUnited States
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruiting
-
Changping LaboratoryNot yet recruitingAphasia | Stroke, Ischemic
-
Chang Gung Memorial HospitalCompletedCerebral Vascular AccidentTaiwan
-
University of California, San DiegoUniversity of Pennsylvania; Milken InstituteActive, not recruiting
-
Sunnybrook Health Sciences CentreRecruitingPost Concussion SyndromeCanada
-
Changping LaboratoryRecruiting